Anti-PA2GC/ PLA2G2C functional antibody

Anti-PA2GC/ PLA2G2C functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to PLA2G2C/PLA2G2C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1192-Ab-1/ GM-Tg-hg-SE1192-Ab-2Anti-Human PLA2G2C monoclonal antibodyHuman
GM-Tg-rg-SE1192-Ab-1/ GM-Tg-rg-SE1192-Ab-2Anti-Rat PLA2G2C monoclonal antibodyRat
GM-Tg-mg-SE1192-Ab-1/ GM-Tg-mg-SE1192-Ab-2Anti-Mouse PLA2G2C monoclonal antibodyMouse
GM-Tg-cynog-SE1192-Ab-1/ GM-Tg-cynog-SE1192-Ab-2Anti-Cynomolgus/ Rhesus macaque PLA2G2C monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1192-Ab-1/ GM-Tg-felg-SE1192-Ab-2Anti-Feline PLA2G2C monoclonal antibodyFeline
GM-Tg-cang-SE1192-Ab-1/ GM-Tg-cang-SE1192-Ab-2Anti-Canine PLA2G2C monoclonal antibodyCanine
GM-Tg-bovg-SE1192-Ab-1/ GM-Tg-bovg-SE1192-Ab-2Anti-Bovine PLA2G2C monoclonal antibodyBovine
GM-Tg-equg-SE1192-Ab-1/ GM-Tg-equg-SE1192-Ab-2Anti-Equine PLA2G2C monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1192-Ab-1/ GM-Tg-hg-SE1192-Ab-2; GM-Tg-rg-SE1192-Ab-1/ GM-Tg-rg-SE1192-Ab-2;
GM-Tg-mg-SE1192-Ab-1/ GM-Tg-mg-SE1192-Ab-2; GM-Tg-cynog-SE1192-Ab-1/ GM-Tg-cynog-SE1192-Ab-2;
GM-Tg-felg-SE1192-Ab-1/ GM-Tg-felg-SE1192-Ab-2; GM-Tg-cang-SE1192-Ab-1/ GM-Tg-cang-SE1192-Ab-2;
GM-Tg-bovg-SE1192-Ab-1/ GM-Tg-bovg-SE1192-Ab-2; GM-Tg-equg-SE1192-Ab-1/ GM-Tg-equg-SE1192-Ab-2
Products NameAnti-PLA2G2C monoclonal antibody
Formatmab
Target NamePLA2G2C
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PLA2G2C benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1192-Ag-1Recombinant multi-species PA2GC/ PLA2G2C protein


    Target information

    Target IDGM-SE1192
    Target NamePLA2G2C
    Gene ID391013,18781,29387,717084,102151235,101092035,504978,100071826
    Gene Symbol and SynonymsPLA2G2C,UBXN10-AS1
    Uniprot AccessionQ5R387,P39878
    Uniprot Entry NamePA2GC_HUMAN,PA2GC_RAT
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000187980
    Target ClassificationN/A

    The target: PLA2G2C, gene name: PLA2G2C, also named as . Predicted to enable calcium ion binding activity; calcium-dependent phospholipase A2 activity; and phospholipid binding activity. Predicted to be involved in phospholipid metabolic process. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.